Acrivon Therapeutics, Inc. (ACRV)
(Real Time Quote from BATS)
$6.13 USD
-0.13 (-2.08%)
Updated Jun 25, 2024 11:02 AM ET
2-Buy of 5 2
F Value F Growth A Momentum D VGM
Brokerage Reports
Acrivon Therapeutics, Inc. [ACRV]
Reports for Purchase
Showing records 1 - 12 ( 12 total )
Company: Acrivon Therapeutics, Inc.
Industry: Medical - Drugs
1Q24 Recap: Additional Updates on ACR-368 and AP3 Platform Expected in 2H24; PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Acrivon Therapeutics, Inc.
Industry: Medical - Drugs
Initial ACR-368 Phase 2 Data Promising, Demonstrating Platform Validation, Though Still Early
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Acrivon Therapeutics, Inc.
Industry: Medical - Drugs
PIPE Financing Raises Confidence in ACR-368 Phase 2 Data in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Acrivon Therapeutics, Inc.
Industry: Medical - Drugs
4Q23 Recap: Eyes on ACR-368 Phase 2 Data in 1H24; We View Benefit/Risk as Favorable
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Acrivon Therapeutics, Inc.
Industry: Medical - Drugs
Company: Acrivon Therapeutics, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for ACRV 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Acrivon Therapeutics, Inc.
Industry: Medical - Drugs
3Q23 Recap: More Mature ACR-368 Data Update Guided to 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Acrivon Therapeutics, Inc.
Industry: Medical - Drugs
Dual WEE1 and PKMYT1 Inhibitor to Advance Into IND-Enabling Studies
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Acrivon Therapeutics, Inc.
Industry: Medical - Drugs
2Q23 Recap: Initial ACR-368 Phase 2 Data in 2H23 Could Be a Significant Catalyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Acrivon Therapeutics, Inc.
Industry: Medical - Drugs
1Q23 Recap: Timelines Remain on Track; Focus Is on Phase 2 Data in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Acrivon Therapeutics, Inc.
Industry: Medical - Drugs
AP3 Platform Identifies Drug Specific Biomarkers, Resistance Mechanisms and Combination Approaches
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Acrivon Therapeutics, Inc.
Industry: Medical - Drugs
Patient Selection Platform Which Could Potentially Increase Response Rates to Drugs; Initiating at Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
|